Celtaxsys, Inc.

Celltaxis, LLC

Eric B Springman

Lopa Bhatt

Ralph Grosswald

William J Guilford

Margaret McCrann Pugh

Kurt Roinestad

Tom Kirkland

Sanjeev Ahuja

Gregory S Duncan

Margaret Mccrann Pugh

Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.

Method of reducing pulmonary exacerbations in respiratory disease patients

The present invention is directed to methods of inhibiting LTA-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene Ahydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.

Methods of inhibiting leukotriene A4 hydrolase

This present disclosure is directed to compounds of formula (I): 

Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase

This present disclosure is directed to compounds of formula (I):  where R, R, Y, and Z are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene Ahydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.

Inhibitors of leukotriene A4 hydrolase

Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase

Growing community of inventors

Atlanta, GA, United States of America

Eric B Springman